Meet the Team
IND is comprised of an accomplished team of physician investigators, study coordinators, neuropsychologists and imaging technologists. Our Board of Directors and Advisory Board provide invaluable support and oversight.
Kenneth Marek, MD, President and Senior Scientist
John Seibyl, MD, CEO and Senior Scientist
Danna Jennings, MD, Director of Clinical Research
David S. Russell, MD, PhD, Associate Director of Clinical Research
Gilles Tamagnan, PhD, Director of Laboratory Research & Development.
IND Board of Directors
IND Advisory Board
Kenneth Marek, M.D., President, Co-Founder, Senior Scientist.
Dr. Marek serves as President of IND and was until March, 2001 Director of the Movement Disorders Center at the Yale University School of Medicine. He graduated from Princeton University (AB, biochemistry) and received his medical degree from Yale University. Dr. Marek was trained in internal medicine and neurology at the Johns Hopkins School of Medicine in Baltimore, Maryland. He received further training as a post-doctoral fellow in neurochemistry at the Institute of Neurology, Queens Square, London. Prior to his move to Yale University he was a faculty member of the Johns Hopkins School of Medicine, Department of Neurology. Dr. Marek has been the recipient of numerous grants and awards, including those from the National Institutes of Health (NIH), Department of Defense, American Heart Association, Parkinson Disease Foundation, and National Parkinson’s Foundation. He has been a recipient of the National Parkinson’s Foundation Richard E. Heikala Research Scholar Award. He currently serves on the scientific advisory board of the Michael J. Fox Foundation. He is currently CEO of Molecular NeuroImaging, LLC, and Clinical Professor of Neurology at Yale University. Dr. Marek has made significant research contributions in the identification of biomarkers for early detection, assessment of disease progression and development of new treatments for Parkinson disease and related neurodegenerative disorders, including Huntington disease, Alzheimer disease and dystonia. His specific interest has been in in vivo neuroreceptor imaging in Parkinson disease and related neurodegenerative disorders. He has authored numerous neurology and neuroscience publications on these topics. He has served as a consultant for numerous pharmaceutical companies and for the Veterans Administration. Dr. Marek is the principal investigator of several international studies investigating the use of imaging to assess the onset, progression and effect of treatment in Parkinson disease.
John Seibyl, M.D., CEO, Co-Founder and Senior Scientist
Dr. Seibyl serves as CEO and Senior Scientist at IND and was until July 2001 Chief, Section of Nuclear Medicine and Associate Professor of Diagnostic Radiology and Psychiatry, Yale University School of Medicine. He received his undergraduate degree at Yale College and completed his medical degree at Case-Western Reserve University in Cleveland, Ohio. Dr. Seibyl trained as a post-doctoral fellow in the Department of Psychiatry at Yale University where he won the Seymour Lustman Research Prize in the Department of Psychiatry two consecutive years. He joined the faculty as an Assistant Professor upon completion of this training. While on the psychiatry faculty Dr. Seibyl's interest in brain imaging led to his returning for a training Fellowship in Nuclear Medicine at Yale under Dr. Paul Hoffer. He was recruited to the Diagnostic Radiology faculty and was appointed the Director of the NeuroSPECT Center, a clinical brain imaging research lab in the Section of Nuclear Medicine. Dr. Seibyl subsequently became Chief of the Section of Nuclear Medicine and Director of the Yale/VA PET Center. Dr. Seibyl has won numerous grants and contracts in the context of his work in brain imaging. He serves on the editorial board of the European Journal of Nuclear Medicine and is a frequent reviewer for top-tier nuclear imaging journals. He serves on international panels for his work in neurodegenerative disease imaging, working closely with Dr. Marek to establish the NeuroSPECT Center as the premier Parkinson disease brain imaging research center in the world. Recent projects include the development of a web-based normal brain image database, and on-going work applying brain imaging techniques and analytic methods to improve the diagnosis and assessment of disease status in patients with neurodegenerative diseases.
Danna Jennings, M.D., Clinical Research Director.
Dr. Jennings received her medical degree from Oregon Health & Science University. She received her training in Neurology from Boston University and completed a movement disorders fellowship at Columbia Presbyterian Medical Center in New York. She was a teaching faculty member in the department of neurology at Yale University prior to her position at the Institute for Neurodegenerative Disorders. Dr. Jennings has been an active member of the Parkinson Study Group and the Huntington Study Group. She has developed several investigator initiated multi-center studies and has served as a lead investigator on these trials in addition to 30 clinical trials aimed at the development of improvements in the diagnosis and treatment of neurodegenerative conditions. Dr. Jennings' specific research interests include the development of diagnostic tools to detect changes in the brain that may occur even prior to symptoms in neurodegenerative conditions. She is currently involved in several studies aimed at the development of medications that may modify the rate of progression of neurodegenerative conditions. In addition, she has designed studies that focus on developing a better understanding of risk factors that may play a role in the rate of progression of Alzheimer disease and Parkinson disease.
David S. Russell, M.D., Ph.D. Associate Clinical Research Director.
For 12 years prior to coming to IND, Dr. Russell was a member of the Yale Movement Disorders Clinics, and is currently an Assistant Clinical Professor at the Yale University School of Medicine. At the IND he directs or participates in a number of clinical trials relating to neurodegenerative diseases ranging from Parkinson’s disease to Alzheimer’s disease to multiple sclerosis and others. Dr. Russell received his undergraduate training in Biology at Oberlin College and completed a Medical Scientist Training Program (M.D., Ph.D.) at Cornell University Medical College and the Sloan-Kettering Institute in New York. His internship in Internal Medicine and residency in Neurology were performed at Yale-New Haven Hospital and he was selected as Chief Resident in Neurology for 1994-1995. Over the years, he has directed a number of basic scientific studies related to dopaminergic brain function for over a decade. He has been an active participant in the Parkinson Study Group and served as an investigator in multi-site clinical trials of Parkinson’s disease. In 2007, he expanded his role in clinical trials of neurodegenerative disorders by joining IND. Dr. Russell’s research and clinical interests include investigations of the mechanisms, detection, and potential prevention of neuronal dysfunction, as well as development of early molecular and biomarker indicators of loss or alteration of function of specific brain systems. He has published widely in important neuroscience journals and spoken at numerous national and international meetings.
Gilles Tamagnan, Ph.D. , Laboratory Research and Development Director.
Dr. Tamagnan received his PhD in Medicinal Chemistry at the University Joseph Fourier in Grenoble, France in 1993. After a post-doctoral fellowship spent on the crystallization of protein, Dr. Tamagnan completed a second postdoctoral fellowship at RBI in Boston, Massachusetts. His research subject was to develop new ligands for the diagnosis of Parkinson disease using compounds labeled with radioactive atoms. He joined the NeuroImaging program at Yale University in June 1997 to work on the development of new radioligands to study neurodegenerative diseases and came to IND in 2003. Dr. Tamagnan has been the recipient of numerous grants and is the co-inventor of ligands used for the diagnosis of Parkinson disease. He joined IND as Laboratory Research and Development Director in 2003.
Board of Directors
IND relies on its Board of Directors to promote, support and maintain its mission.
Michael Forte, Esq., Chairman
Harvey Dann, Trustee, Helen I. Graham Charitable Foundation
Jacqueline Dorwin, Co-founder, Connecticut Parkinson’s Working Group
Kenneth Marek, MD, President of IND
Fred Poulos, Founder, Walk with Fred
John Seibyl, MD, CEO of IND
IND’s advisors support the mission by providing funding, expertise and time.
Howard Zwickler, EdD, Chairman, Retired Business Manager of Fairfield Public Schools
Rasheda Ali-Walsh, Author and Actress
Gayle Aufderheide, Chair, Nutmeg Securities
Al Bishop, Owner, Bishops Orchards
Judge Lawrence Hauser, Superior Court, Connecticut
Connecticut State Senator Gary LeBeau
Elizabeth Ann McCaffrey, Founder, Branford Parkinson Research Walk
Karen Pritzker, President, Seedlings Foundation